{
    "nctId": "NCT00319748",
    "title": "Phase II Study of 852A Administered Subcutaneously in Patients With Metastatic Refractory Breast, Ovarian, Endometrial and Cervical Cancers",
    "symPyJSON": {
        "type": "and",
        "operands": [
            {
                "type": "and",
                "operands": [
                    {
                        "type": "or",
                        "operands": [
                            {
                                "type": "variable",
                                "value": "Breast - Karnofsky score > 50"
                            },
                            {
                                "type": "variable",
                                "value": "Ovarian, endometrial or cervical - Gynecologic Oncology Group (GOG) performance score \u22642"
                            }
                        ]
                    },
                    {
                        "type": "variable",
                        "value": "If female and of childbearing potential, are willing to use adequate contraception prior to study entry and for the duration of study participation"
                    },
                    {
                        "type": "variable",
                        "value": "Normal organ function within 14 days of study entry"
                    },
                    {
                        "type": "or",
                        "operands": [
                            {
                                "type": "variable",
                                "value": "Diagnosis of Metastatic breast cancer (BR)"
                            },
                            {
                                "type": "variable",
                                "value": "Diagnosis of Metastatic ovarian cancer (OV)"
                            },
                            {
                                "type": "variable",
                                "value": "Diagnosis of Metastatic endometrial cancer (EM)"
                            },
                            {
                                "type": "variable",
                                "value": "Diagnosis of Metastatic cervical cancer (CX)"
                            }
                        ]
                    },
                    {
                        "type": "variable",
                        "value": "Measurable metastatic disease (>1cm) in at least one site other than bone-only for Breast Cancer"
                    },
                    {
                        "type": "variable",
                        "value": "Progression on or failure to respond to at least one previous chemotherapy regimen for metastatic disease for Breast Cancer"
                    },
                    {
                        "type": "implies",
                        "operands": [
                            {
                                "type": "variable",
                                "value": "Progression on prior therapy with a hormonal agent if estrogen receptor or progesterone receptor positive, and/or with trastuzumab if HER2-neu positive for Breast Cancer"
                            },
                            {
                                "type": "variable",
                                "value": "If patient has progressed through hormone or trastuzumab therapy only, must have received one chemotherapy regimen for Breast Cancer"
                            }
                        ]
                    },
                    {
                        "type": "variable",
                        "value": "Measurable metastatic disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) for Ovarian Cancer"
                    },
                    {
                        "type": "variable",
                        "value": "Primary tumor must have been diagnosed histologically as either epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer (not borderline or low malignant potential epithelial carcinoma) for Ovarian Cancer"
                    },
                    {
                        "type": "variable",
                        "value": "Subjects must have failed at least two previous chemotherapy regimens for Ovarian Cancer"
                    },
                    {
                        "type": "variable",
                        "value": "Paclitaxel must have been a component of one or both regimens for Ovarian Cancer"
                    },
                    {
                        "type": "variable",
                        "value": "Cisplatin or carboplatin must have been a component of one or both regimens for Ovarian Cancer"
                    },
                    {
                        "type": "variable",
                        "value": "Measurable metastatic disease for Endometrial Cancer"
                    },
                    {
                        "type": "and",
                        "operands": [
                            {
                                "type": "variable",
                                "value": "Histologically proven recurrent or persistent endometrial cancer that is not amenable to curative treatment with surgery and/or radiation therapy for Endometrial Cancer"
                            },
                            {
                                "type": "variable",
                                "value": "Has failed 2 previous treatment regimens for Endometrial Cancer"
                            }
                        ]
                    },
                    {
                        "type": "variable",
                        "value": "Measurable metastatic disease for Cervical Cancer"
                    },
                    {
                        "type": "and",
                        "operands": [
                            {
                                "type": "variable",
                                "value": "Histologically proven recurrent or persistent squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix that is not amenable to curative treatment with surgery and/or radiation therapy for Cervical Cancer"
                            },
                            {
                                "type": "variable",
                                "value": "Has failed 2 previous treatment regimens for Cervical Cancer"
                            }
                        ]
                    },
                    {
                        "type": "variable",
                        "value": "Must have minimum age of 18 Years for Cervical Cancer"
                    }
                ]
            },
            {
                "type": "not",
                "operands": [
                    {
                        "type": "or",
                        "operands": [
                            {
                                "type": "variable",
                                "value": "Systemic corticosteroids (oral or injectable) within 7 days of first dose of 852A"
                            },
                            {
                                "type": "variable",
                                "value": "Investigational drugs/agents within 14 days of first dose of 852A"
                            },
                            {
                                "type": "variable",
                                "value": "Immunosuppressive therapy, including cytotoxic agents within 14 days of first dose of 852A (nitrosoureas within 30 days of first dose)"
                            },
                            {
                                "type": "variable",
                                "value": "Drugs known to induce QT interval prolongation and/or induce Torsades de pointes unless best available drug required to treat life-threatening conditions"
                            },
                            {
                                "type": "variable",
                                "value": "Radiotherapy within 3 weeks of the first dose of 852A"
                            },
                            {
                                "type": "variable",
                                "value": "Hematopoietic cell transplantation within 4 weeks of first dose of 852A"
                            },
                            {
                                "type": "variable",
                                "value": "Evidence of active infection within 3 days of first dose of 852A"
                            },
                            {
                                "type": "variable",
                                "value": "Active fungal infection or pulmonary infiltrates (prior treated disease stable for 2 weeks is allowable)"
                            },
                            {
                                "type": "variable",
                                "value": "Cardiac ischemia, cardiac arrhythmias or congestive heart failure uncontrolled by medication"
                            },
                            {
                                "type": "variable",
                                "value": "History of, or clinical evidence of, a condition which, in the opinion of the investigator, could confound the results of the study or put the subject at undue risk"
                            },
                            {
                                "type": "variable",
                                "value": "Uncontrolled intercurrent or chronic illness"
                            },
                            {
                                "type": "variable",
                                "value": "Active autoimmune disease requiring immunosuppressive therapy within 30 days"
                            },
                            {
                                "type": "variable",
                                "value": "Active coagulation disorder not controlled with medication"
                            },
                            {
                                "type": "variable",
                                "value": "Pregnant or lactating"
                            },
                            {
                                "type": "variable",
                                "value": "Concurrent malignancy (if in remission, at least 5 years disease free) except for localized (in-situ) disease, basal carcinomas and cutaneous squamous cell carcinomas that have been adequately treated"
                            },
                            {
                                "type": "variable",
                                "value": "Any history of brain metastases or any other active central nervous system (CNS) disease"
                            }
                        ]
                    }
                ]
            }
        ]
    },
    "symPyExpression": "And(Symbol('Cisplatin or carboplatin must have been a component of one or both regimens for Ovarian Cancer'), Symbol('Has failed 2 previous treatment regimens for Cervical Cancer'), Symbol('Has failed 2 previous treatment regimens for Endometrial Cancer'), Symbol('Histologically proven recurrent or persistent endometrial cancer that is not amenable to curative treatment with surgery and/or radiation therapy for Endometrial Cancer'), Symbol('Histologically proven recurrent or persistent squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix that is not amenable to curative treatment with surgery and/or radiation therapy for Cervical Cancer'), Symbol('If female and of childbearing potential, are willing to use adequate contraception prior to study entry and for the duration of study participation'), Symbol('Measurable metastatic disease (>1cm) in at least one site other than bone-only for Breast Cancer'), Symbol('Measurable metastatic disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) for Ovarian Cancer'), Symbol('Measurable metastatic disease for Cervical Cancer'), Symbol('Measurable metastatic disease for Endometrial Cancer'), Symbol('Must have minimum age of 18 Years for Cervical Cancer'), Symbol('Normal organ function within 14 days of study entry'), Symbol('Paclitaxel must have been a component of one or both regimens for Ovarian Cancer'), Symbol('Primary tumor must have been diagnosed histologically as either epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer (not borderline or low malignant potential epithelial carcinoma) for Ovarian Cancer'), Symbol('Progression on or failure to respond to at least one previous chemotherapy regimen for metastatic disease for Breast Cancer'), Symbol('Subjects must have failed at least two previous chemotherapy regimens for Ovarian Cancer'), Implies(Symbol('Progression on prior therapy with a hormonal agent if estrogen receptor or progesterone receptor positive, and/or with trastuzumab if HER2-neu positive for Breast Cancer'), Symbol('If patient has progressed through hormone or trastuzumab therapy only, must have received one chemotherapy regimen for Breast Cancer')), Or(Symbol('Breast - Karnofsky score > 50'), Symbol('Ovarian, endometrial or cervical - Gynecologic Oncology Group (GOG) performance score \u22642')), Or(Symbol('Diagnosis of Metastatic breast cancer (BR)'), Symbol('Diagnosis of Metastatic cervical cancer (CX)'), Symbol('Diagnosis of Metastatic endometrial cancer (EM)'), Symbol('Diagnosis of Metastatic ovarian cancer (OV)')), Not(Or(Symbol('Active autoimmune disease requiring immunosuppressive therapy within 30 days'), Symbol('Active coagulation disorder not controlled with medication'), Symbol('Active fungal infection or pulmonary infiltrates (prior treated disease stable for 2 weeks is allowable)'), Symbol('Any history of brain metastases or any other active central nervous system (CNS) disease'), Symbol('Cardiac ischemia, cardiac arrhythmias or congestive heart failure uncontrolled by medication'), Symbol('Concurrent malignancy (if in remission, at least 5 years disease free) except for localized (in-situ) disease, basal carcinomas and cutaneous squamous cell carcinomas that have been adequately treated'), Symbol('Drugs known to induce QT interval prolongation and/or induce Torsades de pointes unless best available drug required to treat life-threatening conditions'), Symbol('Evidence of active infection within 3 days of first dose of 852A'), Symbol('Hematopoietic cell transplantation within 4 weeks of first dose of 852A'), Symbol('History of, or clinical evidence of, a condition which, in the opinion of the investigator, could confound the results of the study or put the subject at undue risk'), Symbol('Immunosuppressive therapy, including cytotoxic agents within 14 days of first dose of 852A (nitrosoureas within 30 days of first dose)'), Symbol('Investigational drugs/agents within 14 days of first dose of 852A'), Symbol('Pregnant or lactating'), Symbol('Radiotherapy within 3 weeks of the first dose of 852A'), Symbol('Systemic corticosteroids (oral or injectable) within 7 days of first dose of 852A'), Symbol('Uncontrolled intercurrent or chronic illness'))))"
}